Anti-obesity Drugs Market Rising in United States | Fortune Business Insights
The global anti-obesity drugs market size is set to grow significantly owing to the ever-increasing prevalence of obesity among the global population, observes Fortune Business Insights™ in its report, titled, “Anti-obesity Drugs Market Size, Share & COVID-19 Impact Analysis, By Type (Prescription Drugs and OTC Drugs), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027.” The market size was USD 1,520.2 million in 2019 and is anticipated to reach USD 3,421.0 million by 2027, exhibiting a CAGR of 10.1% during the forecast period.
Get Sample PDF Brochure:
https://www.fortunebusinessinsights.com/enquiry/sample/anti-obesity-drugs-market-104783
|
North America |
United States, Canada and Mexico |
|
Europe |
Germany, UK, France, Italy, Russia and Turkey
etc. |
|
Asia-Pacific |
China, Japan, Korea, India, Australia, Indonesia,
Thailand, Philippines, Malaysia and Vietnam etc. |
|
South America |
Brazil, Argentina, Columbia etc. |
|
Middle East & Africa |
Saudi Arabia, UAE, Egypt, Nigeria and South
Africa |
Rising Prevalence of Obesity Worldwide to Drive Growth
Owing to poor
lifestyle choices and unhealthy eating habits, the world is on the verge of an
obesity pandemic. The increasing cases of obesity worldwide are driving the
anti-obesity drugs market growth. For instance, according to the World Obesity
Federation, there are 650 million adults along with 120 million children
currently suffering from obesity. In addition, increasing research and
development activities by key players to introduce effective anti-obesity drugs
are estimated to further enhance growth. However, the lack of knowledge
regarding the efficacy of such anti-obesity drugs may hinder growth in the
future.
New Product Launches to Aid Key Players Gain
Prominence
Key players
operating in the global market are focusing on innovative product launches in
order to expand their customer base. In addition, the development of new
anti-obesity pharma drugs will help them gain prominence over other players.
For instance, Novo Nordisk has seven pipeline candidates indicated against
obesity, which are currently in various stages of development.
Healthcare Sector to Stumble amid COVID-19 Pandemic
The healthcare sector has been the most active ever
since the COVID-19 outbreak. While the pandemic has fast-tracked the
development of the industry on a global scale, it has also brought numerous
adversities upon the sector. These adversities include limited infrastructure
in developing countries and the lack of preparedness in case of health
emergencies. Key players are focusing on eliminating such challenges. At
Fortune Business Insights, we are constantly analyzing the market conditions to
offer the most effective solutions at your service.
About Us:
Fortune Business Insights™ delivers accurate data and innovative
corporate analysis, helping organizations of all sizes make appropriate
decisions. We tailor novel solutions for our clients, assisting them to address
various challenges distinct to their businesses. Our aim is to empower them
with holistic market intelligence, providing a granular overview of the market
they are operating in.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Comments
Post a Comment